EAM
AVDL

Exome Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Exome Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-209,092
Closed -$2.94M – 64
2024
Q2 		$2.94M Buy
+209,092
New +$3.41M 2.62% 11

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Exome Asset Management's AVDL Position: Q3 2024 in Review

Exome Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2024, closing a stake of 209,092 shares — an estimated $2.94M sold.

Exome Asset Management first reported a position in AVDL in Q2 2024 and held it in 1 quarter. The position peaked at $2.94M in Q2 2024. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

  • Exome Asset Management reported no remaining Avadel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Exome Asset Management sold 209,092 Avadel Pharmaceuticals shares in Q3 2024, an estimated $2.94M.
  • Exome Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Exome Asset Management's Avadel Pharmaceuticals position peaked at $2.94M in Q2 2024.
  • 176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on Exome Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.